… and Expert Consensus Documents produced by Task Forces, expert groups or consensus
… The Task Force has classified and ranked the usefulness or efficacy of the recommended …

• The most familiar angiotensin-converting enzyme subtype, angiotensin-converting enzyme-1
(kininase II), cleaves the vasoconstrictor octapeptide angiotensin II from its inactive …

… The Joint Task Force is committed to ensuring that the practice parameters are … Task Force
Reviewers, and peer review by members of each sponsoring society. Although the Task Force …

… EXPLANATION: The initial 2006 National Lipid Association Statin Safety Task Force Expert
Liver Panel recommended that routine liver enzyme testing not be required. Subsequently, in …

Background Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality
and morbidity in patients with chronic heart failure (CHF), but most affected patients are …

… Angiotensin-converting enzyme inhibitors have been consistently shown to be associated
with a greater risk for cough than ARBs (Peto pooled odds ratio, 0.32). For randomized, …

… Angiotensin-converting enzyme inhibitors were studied in seven trials and ARBs in four (Table
1). The definition of AF (new vs. all) and the methods used to document AF were different …

… Angiotensin-converting enzyme inhibition was associated with a reduced incidence of AF
for patients with hypertension in a usual care setting. These results need to be confirmed in a …

… Indeed, angiotensin-converting–enzyme (ACE) inhibitors … inhibitor. These observations
raised the possibility that patients with coronary artery disease might benefit from ACE-inhibitor …

… Angiotensin-converting enzyme 2 is distinct and not directly related to the clinical use of …
Angiotensin-converting enzyme inhibitors target angiotensin-converting enzyme 1 (ACE) to …